Elisabeth Heath, MD
Medical Oncology · Rochester, MNNPI 1700823796
Payments from drug & device makers
Across 1,517 payments — averaging $4093.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$2.5M
- Merck$816K
- Gilead$485K
- Exelixis Inc.$365K
- Bayer$295K
- Seagen Inc.$197K
- plus $1.5M from 29 others
Across 5 payments — averaging $3091.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$11K
- Pfizer$3K
- Astellas Pharma Global Development$853
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 10 | $2,518,339 |
| Merck | 193 | $815,510 |
| Gilead | 143 | $484,821 |
| Exelixis Inc. | 123 | $365,079 |
| Bayer | 342 | $295,266 |
| Seagen Inc. | 126 | $196,874 |
| AstraZeneca | 30 | $194,447 |
| Corcept Therapeutics | 66 | $182,632 |
| E.r. Squibb & Sons, L.L.C. | 16 | $177,065 |
| Macrogenics, Inc. | 63 | $167,389 |
| Pfizer | 60 | $165,930 |
| Sanofi | 58 | $86,206 |
| Eisai Inc. | 96 | $85,044 |
| Eli Lilly | 3 | $83,003 |
| Mirati Therapeutics, Inc. | 29 | $79,634 |
| Janssen Research & Development, LLC | 33 | $75,122 |
| GSK | 9 | $48,116 |
| Roche Products Limited | 19 | $37,449 |
| AVEO Pharmaceuticals, Inc. | 11 | $35,500 |
| Genentech, Inc. | 18 | $19,732 |
| Pharmacyclics LLC, An Abbvie Company | 15 | $19,312 |
| Astellas Pharma Global Development | 18 | $19,035 |
| Novartis | 6 | $14,541 |
| Johnson & Johnson | 9 | $8,209 |
| EMD Serono, Inc. | 1 | $7,125 |
| Immunomedics, Inc. | 1 | $6,857 |
| Caris MPI, Inc. | 3 | $5,618 |
| Boehringer Ingelheim | 1 | $5,101 |
| Bristol Myers Squibb | 3 | $3,728 |
| Sumitomo Pharma America, Inc. | 3 | $2,812 |
| Dendreon Pharmaceuticals LLC | 4 | $2,156 |
| Aadi Bioscience, Inc. | 1 | $1,500 |
| Blue Earth Diagnostics | 1 | $142 |
| Myovant Sciences Inc. | 2 | $55 |
| Lilly USA, LLC | 1 | $17 |
How this compares
$6,209,366 in reported general payments places this provider in the 90th percentile of 133 medical oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Rochester
- Evanthia GalanisRochester$72.3M
- Frank SinicropeRochester$10.3M
- Harry YoonRochester$10.2M
- Konstantinos LeventakosRochester$9.6M
- Matthew BlockRochester$8.1M
- Keith BibleRochester$7.5M
- Jian CampianRochester$7.3M
- Katharine PriceRochester$7M
- Robert McWilliamsRochester$6.3M
- Alton SartorRochester$5.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.